Vitrectomy News and Research

RSS

Support for internal limiting membrane peeling for full-thickness macular holes

Vitrectomy with peeling of the internal limiting membrane of the retina improves the outcome of idiopathic full-thickness macular hole surgery compared with no peeling, study findings show.

1 May 2014

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Exposure for even fractions of a second to high-powered blue handheld laser devices can cause serious eye injuries, according to a study recently released online in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers have concluded that the wide availability of these devices, which are often marketed as toys, could lead to an epidemic of ocular injuries, and greater public awareness and government intervention should be encouraged.

6 Dec 2013

Intravitreal ranibizumab shows little benefit after hemorrhage

Ranibizumab given intravitreally offers no clear benefit in the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy, a randomized clinical trial indicates.

8 Feb 2013

Eight days is magic number for macular reattachment

Individuals who have a macula-off rhegmatogenous retinal detachment for up to 8 days before being treated can expect continued improvement in their visual acuity for up to a year after reattachment surgery, show study results.

23 Nov 2012

One-day seminar to explore ophthalmic innovations

The newest ophthalmic innovations with market potential will be the focus of a one-day seminar in Seattle on May 3, 2013 that will connect scientists, venture capitalists, pharmaceutical representatives and others.

3 Nov 2012

Gas superior to air tamponade in lower quadrant vitrectomy

Gas and air are suitable tamponading agents for use during vitrectomy for rhegmatogenous retinal detachment, however air tamponade should only be used in cases that are restricted to the superior quadrants, study findings show.

30 Oct 2012

FDA approves 'first non-surgical treatment' for vitreomacular adhesion

The US Food and Drug Administration reports the approval of ocriplasmin for the treatment of symptomatic vitreomacular adhesion.

26 Oct 2012

ThromboGenics receives FDA approval for Jetrea to treat symptomatic vitreomacular adhesion

On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

19 Oct 2012

Useful vision maintained long term after lens-sparing vitrectomy for ROP

Infants treated with lens-sparing vitrectomy for retinopathy of prematurity maintain a level of visual acuity necessary for useful vision into their eighth year of life, study results show.

31 Aug 2012

Risk factors defined for retinal detachment after cataract surgery

Study results spanning 22 years show that the risk for retinal detachment after undergoing phacoemulsification for cataracts has fallen dramatically, but that younger, and male patients are more at risk for this adverse outcome than their older, female peers.

20 Jul 2012

African-Americans with glaucoma have higher oxygen levels than Caucasians

Measuring oxygen during eye surgery, investigators at Washington University School of Medicine in St. Louis have discovered a reason that may explain why African-Americans have a higher risk of glaucoma than Caucasians.

12 Jul 2011

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Synergetics launches fully disposable instrument line for retinal surgery

Synergetics USA, Inc., a medical device company that designs, manufactures, and markets innovative microsurgical instruments for ophthalmic and neurosurgical applications, today announced the launch of its newest fully disposable line of hand-held instruments for retinal surgery, Pinnacle 360oTM. The launch occurred at Vail Vitrectomy 2010, a surgical meeting held on March 13 - 17, 2010.

17 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

Comprehensive up-date on pharmacology-assisted vitreoretinal surgery

Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied.

23 Dec 2009